Regeneron aims for intracellular targets via Alnylam deal

Via an RNAi deal with Alnylam covering ocular and CNS diseases as well as certain targets in the liver, Regeneron is aiming to reach intracellular targets, complementing its experience in antibodies and cell-surface targets. The deal comes as Alnylam and Sanofi ended the research and option phase of their 2014 deal.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) will pay

Read the full 567 word article

User Sign In